Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Utility of Antipsychotic Plasma Levels in Schizophrenia
NCT02462473Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2015
- Primary completion
- Jan 2016
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in schizophrenia and schizoaffective disorder (3 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants With Medication Treatment Modifications. Started May 2015; status: terminated.
02
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT02462473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02462473.